Key Takeaways
- Kaynes Technology’s Q4 FY24 revenue of ₹1,243 crore fell 27% short of its own guidance of ₹1,700 crore, triggering a 19.4% plunge in its BSE share price to ₹3,366.
- Profit declined 22% year‑on‑year to ₹91 crore, while operating cash flow turned negative at ₹4.6 billion.
- Working‑capital metrics deteriorated sharply, with net working‑capital days rising to 125 days (guidance 85‑100) and Morgan Stanley estimating 137 days.
- Brokerages reacted swiftly: JPMorgan downgraded to Neutral (target ₹4,000), Nuvama cut to Hold (target ₹3,550), while Morgan Stanley held Equal‑weight (target ₹3,663) and CLSA kept Outperform (target ₹4,200) but warned of a “show‑me” stock until guidance aligns with results.
- Valuation multiples were trimmed across the board; Nuvama now values Kaynes at 35× FY29 earnings with an 18% discount, noting the stock trades at 70×/53×/35× FY27‑FY29 earnings—leaving little margin for further execution slips.
Overview of the Q4 Results and Market Reaction
Kaynes Technology reported Q4 FY24 revenue of ₹1,243 crore, representing a 26% year‑on‑year increase but falling dramatically below its internal target of ₹1,700 crore. The miss amounted to a 27% shortfall versus guidance and also under‑performed both Street and JPMorgan estimates by 18% and 13%, respectively. The disappointing top‑line figure, coupled with a 22% YoY decline in profit to ₹91 crore, prompted an immediate sell‑off, pushing the stock down as much as 19.4% on the BSE to close at ₹3,366 per share.
Brokerage Downgrades and Target‑Price Cuts
The weak results triggered swift actions from several brokerages. JPMorgan shifted its rating from Overweight to Neutral and slashed its target price from an undisclosed higher level to ₹4,000. Nuvama went a step further, downgrading the stock to Hold and reducing its target price to ₹3,550 from ₹5,500—a near‑36% cut. Morgan Stanley maintained its Equal‑weight stance with a target of ₹3,663, while CLSA retained an Outperform rating but lowered its target to ₹4,200, acknowledging the results as a clear negative.
Revenue Guidance Miss and Analyst Commentary
JPMorgan highlighted that the earnings shortfall persisted even after accounting for its own lowered forecasts, noting the results missed both Street and JPMorgan estimates. The brokerage cautioned that, despite expecting a robust 40%/45% compound annual growth rate (CAGR) in revenue and earnings over FY26‑28E driven by the ramp‑up of OSAT and PCB businesses, the stock would remain a “show‑me” investment until the gap between actual performance and company guidance narrows.
Working‑Capital Deterioration
A major point of concern for analysts was the company’s working‑capital trajectory. Net working‑capital days rose to 125 days, well above the guided range of 85‑100 days. Morgan Stanley estimated an even higher figure of 137 days, up from 95 days a year earlier. CLSA calculated an 85‑day year‑on‑year increase in working capital, with net debt standing at ₹711 million. The rise in working‑capital days signals strained liquidity and higher financing needs, which weighed on investor sentiment.
Cash Flow and Balance‑Sheet Pressure
Operating cash flow turned negative at ₹4.6 billion, underscoring the cash‑consumption pressure from the deteriorating working‑capital position. CLSA noted that the balance sheet had deteriorated further ahead of the results, a factor that amplified worries about the company’s financial health. The combination of shrinking cash generation and rising debt levels heightened the risk profile perceived by the market.
Margin Contraction and Cost Pressures
Morgan Stanley pointed out that Q4 EBITDA margin contracted by 145 basis points year‑on‑year to 15.6%. The profit after tax (PAT) miss was attributed to operational weakness compounded by higher interest and depreciation expenses. The brokerage said it is awaiting segment‑wise details and an updated order book before making any further rating adjustments, indicating that the current outlook remains contingent on clearer operational visibility.
Earnings Multiple Revisions
In response to the weaker outlook, JPMorgan reduced its core EMS (Electronic Manufacturing Services) multiple from 45× to 33×, reflecting both lower revenue growth expectations for the next two years and the increased net working‑capital days embedded in its discounted cash‑flow model. Consequently, JPMorgan trimmed earnings forecasts by 12‑17% for FY27‑FY28 across the core EMS, OSAT, and PCB segments. Nuvama was more aggressive, cutting FY27 and FY28 EPS by 22% and 20%, respectively, and now values Kaynes at 35× FY29 earnings with an 18% discount, arriving at its March 2027 target price of ₹3,550.
Current Valuation and Market Implications
At the prevailing market price, Nuvama observed that Kaynes trades at 70×/53×/35× FY27/FY28/FY29 estimated earnings—a valuation that leaves little cushion for continued execution missteps. The tight multiples suggest that investors are pricing in a high degree of risk, and any further disappointments could trigger additional downside pressure. Analysts uniformly stress the need for the company to close the guidance‑performance gap, improve working‑capital efficiency, and demonstrate sustainable margin expansion to regain confidence.
Conclusion and Outlook
Kaynes Technology’s Q4 FY24 results delivered a triple blow: a substantial revenue guidance miss, deteriorating balance‑sheet and working‑capital metrics, and a sharp profit decline. The market reacted with a steep share‑price drop and a wave of brokerage downgrades and target‑price reductions. While long‑term growth drivers such as OSAT and PCB expansion remain intact, the near‑term outlook hinges on the company’s ability to align operational execution with its ambitious guidance, tighten working‑capital management, and restore positive cash flow. Until those improvements materialize, the stock is likely to remain volatile and closely watched by investors seeking clearer evidence of a turnaround.